 Compugen is an early-stage biotechnology company developing cancer immunotherapies from predictive computational discovery platforms. Compugen has an early-stage pipeline of three computationally-discovered therapeutic programs COM701, COM902, and BAY 1905254 targeting immune checkpoints across various combination and monotherapy trials for various cancer-indications. 